Clinical Updates & Insights

Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many t...

A newly published pooled analysis of the Organ Preservation in Patients with Rectal Adenocarcinoma (OPRA) trial and the CAO/ARO/AIO-12 trial by the Ger...

A retrospective study of patients with distal rectal cancer at Memorial Sloan Kettering Cancer Center (MSK) has found a higher rate of local recurrence after intersphincteric resection with handsewn coloanal anastomosis (ISR-CAA) than with abdominoperineal resection (APR) in patients without a clinical response to neoadjuvant therapy who underwent total mesorectal excision (TME).

A five-year study has found that adding daratumumab (D) to the current standard-of-care triplet therapy bortezomib, lenalidomide, and dexamethasone (VRd) produced deeper and more durable minimal residual disease (MRD) responses compared to VRd alone in patients with newly diagnosed, transplant-ineligible multiple myeloma.

On December 4, 2024, the U.S. Food and Drug Administration granted accelerated approval to zenocutuzumab (Bizengri®), the first approved systemic therapy for patients with advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) fusion and pancreatic adenocarcinoma harboring a (NRG1) fusion.

Physicians and researchers at MSK Kids, Memorial Sloan Kettering Cancer Center’s dedicated pediatric cancer program, achieved several notable advances in 2024, including earning authorization to provide the first gene therapy for sickle cell disease and beta thalassemia, opening a new program for patients with desmoplastic small round cell tumors, translating groundbreaking tumor evolution insights into a new clinical trial strategy for patients with osteosarcoma, and leading cutting-edge research for improving patient outcomes after CAR T cell therapy.

A groundbreaking international study has found that imlunestrant plus abemaciclib significantly improved progression-free survival (PFS) versus imlunestrant monotherapy in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer, regardless of prior CDK 4/6 inhibitors, ESR1 or PI3K pathway mutations.

Memorial Sloan Kettering Cancer Center (MSK) researchers presented results of their latest research at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition held in San Diego from December 7 to 10, 2024.

A Q&A with Jaap-Jan Boelens, MD, PhD, Chief of the Pediatric Transplant and Cellular Therapy Service at MSK.

A new study by a team of 12 thoracic surgeons at Memorial Sloan Kettering Cancer Center (MSK), published recently in the Annals of Surgery,([i]) is the first to identify a comprehensive list of clinical factors significantly associated with referring patients with stage 1 NSCLC to SBRT.